AESI — Adverse Events of Special Interest

An Adverse Event of Special Interest is a specific category vaccine safety surveillance uses that most conventional drug PV doesn’t rely on nearly as heavily: a pre-specified event, defined in advance — often before a vaccine is even deployed at scale — that warrants especially close, proactive monitoring because of its severity, a known or theoretical biological mechanism connecting it to vaccination, or its potential to significantly affect public confidence in the immunization programme if it turns out to be genuinely linked.

The proactive framing matters enormously. Rather than waiting for spontaneous reports of an unusual event to accumulate — the reactive pattern Module 7 built for conventional signal detection — an AESI gets actively monitored from the start, which allows a surveillance system to establish a background incidence rate for that specific event in the unvaccinated or general population and then compare it directly against the observed rate in vaccinated populations. That observed-versus-expected comparison can detect a genuine signal far faster and with much more statistical confidence than waiting for the event to eventually surface through general spontaneous reporting and cross a disproportionality threshold.

Getting this proactive monitoring to work consistently across different countries, different surveillance systems, and different research groups requires a shared, precise definition of what actually counts as the event in question — which is exactly what Brighton Collaboration case definitions provide. Brighton Collaboration is an international, independent group that develops standardised diagnostic criteria for specific AESIs, so that "myocarditis" or "Guillain-Barré syndrome" flagged in a US surveillance system means the same specific clinical picture, diagnosed against the same criteria, as the same term flagged in a European or Indian system. Without that standardisation, comparing AESI rates across countries would be comparing genuinely different things dressed up in the same words.

Several AESIs became genuinely consequential in recent vaccine programmes, worth knowing specifically because they illustrate how the system is meant to work: myocarditis and pericarditis (inflammatory heart conditions), Guillain-Barré syndrome (a rare neurological condition), anaphylaxis (the acute severe allergic reaction Module 6’s "other medically important condition" catch-all would recognise instantly as serious), and thrombosis with thrombocytopenia syndrome (a rare clotting disorder). In each case, proactive AESI monitoring against Brighton Collaboration definitions is what allowed regulators to detect, quantify, and communicate about a genuine signal with far more precision and speed than passive spontaneous reporting alone would have permitted.